keyword
MENU ▼
Read by QxMD icon Read
search

Brexpiprazole

keyword
https://www.readbyqxmd.com/read/28101322/brexpiprazole-and-cariprazine-distinguishing-two-new-atypical-antipsychotics-from-the-original-dopamine-stabilizer-aripiprazole
#1
REVIEW
Joshua S Frankel, Thomas L Schwartz
BACKGROUND: Brexpiprazole and cariprazine are the latest US Food and Drug Administration approved atypical antipsychotics available in the United States. Both function as partial agonists of the dopamine-2 receptor (D2R), a mechanism of action shared with aripiprazole. However, all three differ in their affinities for the D2R as well as for serotonin receptors (5-HTRs). This paper seeks to delineate these pharmacodynamic and clinical differences amongst the three dopamine partial agonist atypical antipsychotic drugs...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28057524/involvement-of-presynaptic-5-ht1a-receptors-in-the-low-propensity-of-brexpiprazole-to-induce-extrapyramidal-side-effects-in-rats
#2
Cedric Mombereau, Jørn Arnt, Arne Mørk
Previous studies have shown that partial and full 5-HT1A receptor agonists reduce antipsychotic-induced catalepsy. Consequently, some antipsychotics combining balanced efficacy between dopamine (DA) D2 antagonism or partial agonism and 5-HT1A receptor agonism have a low propensity to induce extrapyramidal side effects (EPS), as reflected by low cataleptogenic activity in rodents. In the present experiments, we attempted to explore the importance of pre- and postsynaptic 5-HT1A agonistic properties of brexpiprazole and aripiprazole in the context of neurological side-effect liabilities...
January 3, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28044942/emerging-pharmacological-therapies-in-schizophrenia-what-s-new-what-s-different-what-s-next
#3
Leslie Citrome
There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28004621/augmentation-of-phenelzine-with-aripiprazole-and-quetiapine-in-a-treatment-resistant-patient-with-psychotic-unipolar-depression-case-report-and-literature-review
#4
Jonathan M Meyer, Michael A Cummings, George Proctor
Irreversible monoamine oxidase inhibitor (MAOI) antidepressants have significant efficacy in treatment-resistant unipolar depression, but in some instances patients may not achieve remission. Among the adjunctive and augmentation strategies, certain second-generation antipsychotics (SGAs) have approval for inadequate responders to antidepressant therapy, including aripiprazole, brexpiprazole, and quetiapine, with lurasidone and the olanzapine/fluoxetine combination indicated for bipolar depression. Clinicians may eschew SGA options in part due to the limited literature on SGA-MAOI combinations, with only one published case involving aripiprazole, and none for olanzapine, lurasidone, or brexpiprazole...
December 22, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27997809/brexpiprazole-for-the-treatment-of-schizophrenia
#5
Wen-Yu Hsu, Hsien-Yuan Lane, Chieh-Hsin Lin
Limited efficacy on negative and cognitive symptoms and adverse effects of current antipsychotics raise the need of developing new antipsychotics. Brexpiprazole, a new antipsychotic drug approved by the U.S. Food and Drug Administration in July 2015 for the treatment of schizophrenia, is a novel serotonin-dopamine receptor modulator with partial agonist activity at serotonin 1A (5-HT1A) and D2/3 receptors. Areas covered: We reviewed brexpiprazole related in vitro and in vivo studies, including phase II and phase III clinical trials in this article...
December 20, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27991542/adjunctive-treatment-of-brexpiprazole-with-fluoxetine-shows-a-rapid-antidepressant-effect-in-social-defeat-stress-model-role-of-bdnf-trkb-signaling
#6
Min Ma, Qian Ren, Chun Yang, Ji-Chun Zhang, Wei Yao, Chao Dong, Yuta Ohgi, Takashi Futamura, Kenji Hashimoto
Addition of low doses of the atypical antipsychotic drug brexpiprazole with selective serotonin reuptake inhibitors (SSRIs) could promote antidepressant effect in patients with major depressive disorder although the precise mechanisms underlying the action of the combination are unknown. Combination of low dose of brexpiprazole (0.1 mg/kg) and SSRI fluoxetine (10 mg/kg) could promote a rapid antidepressant effect in social defeat stress model although brexpiprazole or fluoxetine alone did not show antidepressant effect...
December 19, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27941419/adjunctive-brexpiprazole-as-a-novel-effective-strategy-for-treating-major-depressive-disorder-a-systematic-review-and-meta-analysis
#7
Seoyoung Yoon, Sang Won Jeon, Young-Hoon Ko, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae, Changsu Han
PURPOSE/BACKGROUND: Brexpiprazole was approved for adjunctive treatment of major depressive disorder (MDD) in 2015. Because only a small number of randomized controlled trials have investigated the use of brexpiprazole in MDD, we performed a meta-analysis. METHODS/PROCEDURES: We systematically searched literatures in PubMed, Cochrane Library database, EMBASE, Google Scholar, and clinicaltrials.gov up to January 2016. The primary efficacy measure was the mean change in total Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline...
February 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27846922/brexpiprazole-in-patients-with-schizophrenia-overview-of-short-and-long-term-phase-3-controlled-studies
#8
Stephen R Marder, Mika Juhani Hakala, Mette Krog Josiassen, Peter Zhang, John Ouyang, Emmanuelle Weiller, Catherine Weiss, Mary Hobart
OBJECTIVE: Review efficacy, safety, and tolerability of brexpiprazole in patients with schizophrenia in short- and long-term phase 3 studies. METHODS: Patients experiencing a current exacerbation of schizophrenia received brexpiprazole in two fixed-dose (2 and 4 mg), 6-week, placebo-controlled studies, one flexible-dose (2-4 mg), 6-week, placebo-control and active reference study, and one fixed-dose (1-4 mg), 52-week, placebo-controlled maintenance study. RESULTS: The efficacy of brexpiprazole was demonstrated in the two short-term fixed-dose studies with statistically significant improvements from baseline in Positive and Negative Syndrome Scale (PANSS) total score compared with placebo...
November 16, 2016: Acta Neuropsychiatrica
https://www.readbyqxmd.com/read/27844095/antidepressant-effects-of-combination-of-brexpiprazole-and-fluoxetine-on-depression-like-behavior-and-dendritic-changes-in-mice-after-inflammation
#9
Min Ma, Qian Ren, Chun Yang, Ji-Chun Zhang, Wei Yao, Chao Dong, Yuta Ohgi, Takashi Futamura, Kenji Hashimoto
RATIONALE: Addition of low doses of atypical antipsychotic drugs with selective serotonin reuptake inhibitors (SSRIs) could promote a rapid antidepressant effect in treatment-resistant patients with major depression. Brexpiprazole, a new atypical antipsychotic drug, has been used as adjunctive therapy for the treatment of major depression. OBJECTIVES: The present study was undertaken to examine whether brexpiprazole could augment antidepressant effects of the SSRI fluoxetine in an inflammation model of depression...
November 15, 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27835722/effects-of-adjunctive-brexpiprazole-on-sleep-disturbances-in-patients-with-major-depressive-disorder-an-open-label-flexible-dose-exploratory-study
#10
Andrew D Krystal, Aurélia Mittoux, Peter Meisels, Ross A Baker
Background: Brexpiprazole is a serotonin-dopamine activity modulator. We evaluated the effects of adjunctive treatment with brexpiprazole on sleep disturbances in patients with DSM-IV-TR major depressive disorder (MDD) and inadequate response to antidepressant treatment. Methods: This study was conducted between September 27, 2013, and August 19, 2014. Patients with inadequate response to antidepressant treatment and sleep disturbances continued treatment with their current antidepressant for 2 weeks...
September 8, 2016: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/27788337/adjunctive-brexpiprazole-for-the-treatment-of-major-depressive-disorder
#11
John L Beyer, Richard H Weisler
The lifetime prevalence of major depressive episodes in the United States is nearly 17%. Clinical trials and clinical effectiveness studies have demonstrated that many patients will fail to achieve remission using traditional monotherapy, contributing to significant morbidity and suffering. Because of this, augmentation strategies have been proposed to improve both treatment response and remission. Areas covered: Brexpiprazole is a second generation antipsychotic (SGA) approved by the US FDA in 2015 as an add-on treatment to an antidepressant medication for the treatment of adults with MDD, based on the results of two large-scale, randomized, placebo-controlled trials...
October 27, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27784751/switching-from-inadequate-adjunctive-or-combination-treatment-options-to-brexpiprazole-adjunctive-to-antidepressant-an-open-label-study-on-the-effects-on-depressive-symptoms-and-cognitive-and-physical-functioning
#12
Maurizio Fava, Takao Okame, Yuki Matsushima, Pamela Perry, Emmanuelle Weiller, Ross A Baker
BACKGROUND: Approximately 50% of patients with major depressive disorder (MDD) do not respond adequately to their antidepressant treatment (ADT), underscoring the need for more effective treatment options. The objective of this study was to investigate the effect of adjunctive brexpiprazole on depressive symptoms in patients with MDD who were not responding to adjunctive or combination therapy of their current ADTs with several different classes of agents (NCT02012218). METHODS: In this 6-week, open-label, phase 3b study, patients with MDD who had an inadequate response to ≥1 adjunctive or combination therapy, in addition to history of ≥1 failure to monotherapy ADT, were switched to adjunctive brexpiprazole...
October 26, 2016: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27781135/adjunctive-brexpiprazole-in-patients-with-major-depressive-disorder-and-anxiety-symptoms-an-exploratory-study
#13
Lori L Davis, Ai Ota, Pamela Perry, Kana Tsuneyoshi, Emmanuelle Weiller, Ross A Baker
BACKGROUND: Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult-to-treat patient. Brexpiprazole is a serotonin-dopamine activity modulator: a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors. The objective of this Phase IIIb study was to explore effectiveness, safety, and tolerability of brexpiprazole adjunctive to antidepressant (ADT) monotherapy in patients with MDD and anxiety symptoms (NCT02013531)...
October 2016: Brain and Behavior
https://www.readbyqxmd.com/read/27693466/cost-effectiveness-of-brexpiprazole-adjunctive-treatment-for-major-depressive-disorder
#14
Matthew Sussman, Jeffrey Yu, Siddhesh A Kamat, Ann Hartry, Susan Legacy, Ruth Duffy, Myrlene Sanon Aigbogun
BACKGROUND: Major depressive disorder (MDD) is a debilitating psychiatric illness with a high cost burden. This analysis evaluates the cost-effectiveness of adjunctive brexpiprazole versus comparator branded adjunctive treatment for MDD and background antidepressant therapy (ADT) alone from a US payer perspective. METHODS: An economic model was developed to assess the cost-effectiveness of brexpiprazole versus comparator adjunctive treatment and ADT alone on total direct medical costs using a 6-week cycle time frame for a total of 48 weeks, with treatment response and remission as primary outcomes...
September 20, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27689026/second-generation-antipsychotics-in-the-treatment-of-major-depressive-disorder-an-update
#15
REVIEW
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Tae-Youn Jun, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae
Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD...
September 2016: Chonnam Medical Journal
https://www.readbyqxmd.com/read/27672485/brexpiprazole-a-new-treatment-option-for-schizophrenia
#16
REVIEW
Jonathan R Scarff
Schizophrenia occurs in approximately 0.3 to 0.7 percent of the world's population and is associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. This article reviews brexpiprazole, a medication recently approved to treat patients with schizophrenia. Brexpiprazole was well-tolerated, and adverse reactions were statistically insignificant...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27571460/the-effect-of-brexpiprazole-in-adult-outpatients-with-early-episode-schizophrenia-an-exploratory-study
#17
Ashok Malla, Ai Ota, Kazuhiro Nagamizu, Pamela Perry, Emmanuelle Weiller, Ross A Baker
The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode schizophrenia (18-35 years old, ≤5 years' duration of illness). Efficacy was assessed by the Positive and Negative Syndrome Scale score (PANSS) and social functioning was assessed by changes from baseline in PANSS modified prosocial subscale, personal and social performance (PSP), and specific levels of functioning (SLOF) scales...
November 2016: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27566723/efficacy-and-safety-of-brexpiprazole-opc-34712-as-maintenance-treatment-in-adults-with-schizophrenia-a-randomized-double-blind-placebo-controlled-study
#18
W Wolfgang Fleischhacker, Mary Hobart, John Ouyang, Andy Forbes, Stephanie Pfister, Robert D McQuade, William H Carson, Raymond Sanchez, Margareta Nyilas, Emmanuelle Weiller
BACKGROUND: Brexpiprazole has previously demonstrated efficacy in acute schizophrenia trials. The objective of this trial was to assess the efficacy, safety, and tolerability of maintenance treatment with brexpiprazole in adults with schizophrenia. METHODS: Patients with an acute exacerbation of psychotic symptoms were converted to brexpiprazole (1-4mg/d) over 1 to 4 weeks and entered a single-blind stabilization phase. Those patients who met stability criteria for 12 weeks were randomized 1:1 to double-blind maintenance treatment with either brexpiprazole (at their stabilization dose) or placebo for up to 52 weeks...
October 13, 2016: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27514300/adverse-effects-of-second-generation-antipsychotics-as-adjuncts-to-antidepressants-are-the-risks-worth-the-benefits
#19
REVIEW
Michael E Thase
Over the past decades, several adjunctive therapies have been introduced for treatment-resistant depression (TRD), and these strategies have ebbed and flowed in popularity. Currently, adjunctive therapy with the second-generation antipsychotics (SGAs) is most commonly used by psychiatrists. Four SGAs are FDA approved for indications related to TRD (aripiprazole, brexpiprazole, olanzapine, and quetiapine extended release); some evidence also supports use of risperidone and ziprasidone as adjunctive therapies...
September 2016: Psychiatric Clinics of North America
https://www.readbyqxmd.com/read/27408517/brexpiprazole-rexulti-a-new-monotherapy-for-schizophrenia-and-adjunctive-therapy-for-major-depressive-disorder
#20
Shannon Eaves, Jose A Rey
Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder.
July 2016: P & T: a Peer-reviewed Journal for Formulary Management
keyword
keyword
64523
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"